Showing results (291-300 of 305) with videos related to

Sort By:
Pageof 31
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Future Oncology (London, England)|March 26, 2021
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myelomaRoman Hájek, Jiří Minařík, Jan Straub, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Hemasphere|October 13, 2025
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platformAdrian Mosquera Orgueira, Marta Sonia Gonzalez Perez, Mattia D'Agostino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
Hemasphere|November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
European Journal of Haematology|October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patientsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Pageof 31